anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:A glucide transfusion liquid, containing a reducing substance of a disaccharide such as maltitol or lactitol, and having improved nutrient supply effect. CONSTITUTION:A glucide transfusion liquid containing at least a reducing substance of a disaccharide in an aqueous solution thereof. The reducing substance is preferably maltitol or lactitol. The concentration ranges of the disaccharide and elements in the electrolyte are preferably within those shown in Table 1. The above-mentioned glucide transfusion liquid has improved nutrient supply effect without direct administration of glucose through veins. Therefore, the glucide transfusion liquid can be used even for patients with reduced saccharide resistance. The maltitol or lactitol is easily obtained respectively by reducing maltose or lactose catalytically or with NaBH4.
Prior studies from others, performed in a different breed, reported that doe rabbits developing between two male siblings (2 M) during gestation display characteristics indicative of masculinization: larger anogenital distance (AGD), larger submandibular glands, and higher chinning frequency than females with zero (0 M) or one (1 M) contiguous brothers. Similar effects are provoked by injecting androgens to the pregnant doe suggesting that prenatal androgen exposure masculinizes female embryos. To further understand the scope of such masculinization we compared 0 M, 1 M, and 2 M females regarding behavioral, neuroendocrine, and somatic parameters, related or not to reproduction. IUP did not impact: body weight, sexual receptivity, mating-induced LH secretion, maternal nest-building, litter size, or milk output. At puberty: a) chinning frequency was: 0 M and males>1 M and 2 M; b) ambulation in open field was lowest in 1 M females and males. IUP effects on AGD were significant only on postnatal day 1: 0 M, 1 M, and males>2 M, in contrast to earlier study. Willingness to nurse at delivery was less frequent in 2 M than in 1 M and 0 M does and correlated with nursing occurrence across lactation. Does that did not nurse at parturition delivered fewer kits/min than those that nursed then, regardless of IUP. The duration of nursing bouts across lactation was significantly longer in the1 M and 2 M does that showed this behavior on postpartum days 1-20. Our findings indicate that IUP is associated with alterations in specific aspects of postpartum maternal behavior.
Techniques for extracting clinical entities from clinical documents are provided. In some embodiments, a non-transitory machine-readable medium stores a program. The program receives a clinical document partitioned into a set of sections. Each section in the set of sections includes a plurality of terms. The program further identifies a section in the set of sections. The program also determines a subset of a plurality of entity recognizers based on a classification of the section. Each entity recognizer in the plurality of entity recognizers is configured to identify terms in the section as being associated with a particular type of data. The program further sends the section to the subset of the entity recognizers for processing. The program also generates a clinical statement based on terms identified in the section by the subset of the plurality of entity recognizers.
The study will be conducted at multiple study centers in the U.S. The study will consist of a screening period lasting up to 5 weeks and a treatment period lasting 8 weeks. Subjects will visit the dental clinic twice during the screening period, at Day 1, and at Weeks 4 and 8 of the study.The study will include a single-center run-in phase during which 12 subjects will be enrolled in order to gain preliminary effectiveness data on the TMJ NextGeneration(TM) device. Following completion of the first 12 subjects, a sample size re-estimation may be conducted in order to verify the initial sample size assumptions of the study. These run-in subjects will not be included in the final analysis of the study. Approximately a total of 153 subjects will be enrolled in the study with subjects allocated 2:1 to the TMJ NextGeneration(TM) and occlusal splint treatment arms, respectively. The study is powered with respect to the dual primary effectiveness endpoints of CFB in bruxism episodes per hour of sleep and CFB in migraine episodes per month.
Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
PURPOSE: Many assessment tools have been proposed for use in clinical practice and research on individuals with temporomandibular disorders (TMD). It aimed to translate the Fonseca Anamnestic Index into Turkish (FAI/T) and examine the responsiveness, reliability and validity of the FAI/T in this study.
MATERIALS AND METHODS: Two hundred forty-nine individuals (207 female/42 male) with TMD were included in this study according to the RDC/TMD (muscle disorders, disc displacement, arthralgia and mixed disorders (muscle disorders and disc displacement)). Reliability was evaluated with test-retest reliability, internal consistency, and reproducibility. Validity was assessed with structural validity, construct validity, content validity, and face validity. In addition, responsiveness and floor and ceiling effects were also examined.
RESULTS: The ICC value (0.906) and Cronbach's α (0.951) of the (FAI/T) were excellent. Following Explarotary Factor Analysis, two factors were extracted, accounting for 51.859% of the total variation. Structural validity, construct validity, content validity, and face validity analyses proved the validity of the FAI/T. The responsiveness analysis showed that the Turkish FAI and its subscales were able to detect change over time.
CONCLUSIONS: The FAI/T has shown excellent reliability and good validity. The FAI/T can assess the symptoms of Turkish-speaking persons with TMD.Clinical Trials registration number: NCT04274985.
BACKGROUND: Cementless femoral fixation in total hip arthroplasty (THA) has increased in prevalence worldwide. However, cementless fixation in elderly patients is controversial due to the risks of periprosthetic fracture and aseptic loosening. This study evaluated outcomes in patients undergoing primary THA utilizing a cementless stem without a collar, comparing those less than 75 years to those older than 75 years.
METHODS: Between 2011 and 2021, there were 2,605 cementless THAs performed by 4 surgeons utilizing a highly porous metal fixation surface without a collar and consistent clinical protocols. There were 469 patients who had an age ≥ 75 years. Revision rates, intraoperative fractures, and 90-day mortality were compared between cohorts. In the ≥ 75 year age group, there were more women, more American Society of Anesthesiologists physical status classification III or IV, a lower body mass index, and more kidney disease, osteoporosis, and thyroid disease (P ≤ .002).
RESULTS: All-cause revision rates trended lower for the ≥75 year age group compared to < 75 year (1.9 versus 3.5%, P = .082) at 20-months of follow-up. Moreover, there was no difference in all-cause femoral component revisions comparing ≥ 75 to < 75 year age groups (1.5 versus 2.2%, P = .375), with only 3 of 10 femoral revisions due to aseptic loosening being in the ≥ 75 year age group. Intraoperative fracture (0.2 versus 0.5%, P = .701) and 90-day mortality (0.2 versus 0.1%, P = .460) did not differ between ≥ 75 and < 75 year age groups.
CONCLUSIONS: Older patients had comparable revision rates compared to younger patients using cementless femoral fixation without a collar. Furthermore, there was no difference in 90-day mortality or intraoperative fracture rates. Study findings provide evidence for the safety and durability of cementless THA using collarless femoral stems in elderly patients ≥ 75 years of age.
LEVEL OF EVIDENCE: III.
The control group will be followed up as a home program by explaining the exercises and giving a brochure. They will be asked to do the exercises regularly for 7 days/week, 2 sessions/day, for eight weeks. Patients in the control group will be followed up by phone once a week.
Gleostine causes myelosuppression that can result in fatal infections and bleeding. Myelosuppression from Gleostine is delayed, dose-related, and cumulative. It usually occurs 4 to 6 weeks after drug administration and persists for 1 to 2 weeks. Thrombocytopenia is generally more severe than leukopenia. Cumulative myelosuppression from Gleostine is manifested by greater severity and longer duration of cytopenias.

Monitor blood counts for at least 6 weeks after each dose. Do not give Gleostine more frequently than every 6 weeks. Adjust dose based on nadir blood counts from prior dose [see Dosage and Administration ( 2.3)].
Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
An acidic polycyclic ether antibiotic cpd. UK 61,689 of formula (I) and its cationic salt are prepd. by a controlled hydrolysis of a cpd. UK-58, 852 and its cationic salt. (I) and its cationic salt are used in a nutrient feed compsn. for controlling an occidiosis in poultry and for improving a feed utilization in animals.
If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
A pharmaceutical filling system for a high volume pharmacy is described. The system can include an outflow conveyor, and an injection conveyor to inject a package located thereon onto the outflow conveyor. The injection conveyor can be adjacent to the outflow conveyor and oriented substantially perpendicular to the outflow conveyor. The system can also include a monitoring system positioned to perform package monitoring of the outflow conveyor and to image the package on the outflow conveyor after the package has been injected onto the outflow conveyor. The monitoring system can be further configured to determine an intended destination of the package based on an identifier detected on the package in the image captured by the monitoring system. A routing device can be positioned to perform package routing of the package to an accumulation area for packages based on the determination of the intended destination of the package.
The invention discloses a lactobacillus fermentum for efficiently synthesizing nicotinamide and resisting photoaging and application thereof. Lactobacillus fermentum (Lactobacillus fermentum) XJC60 with a deposit number GDMCC No:61827. the invention has the beneficial effects that: 1. the lactobacillus fermentum XJC60 disclosed by the invention is derived from Xinjiang cheese with sufficient sunlight, and is an excellent strain derived from local sources. 2. Compared with the traditional anti-photoaging chemical drugs, the invention has the advantages of no toxic or side effect on the ecological environment, no residual risk, greenness and safety. 3. The invention is convenient and safe to use, has no potential harm to human body when being proved in multiple levels of genes, cells and animals, and has the advantages of safety and high efficiency. 5. The lactobacillus fermentum XJC60 is the lactobacillus which is screened from 756 probiotics and has good ultraviolet damage resistance.
The safety and efficacy of DIFICID in pediatric patients 6 months to less than 18 years of age was investigated in a Phase 3, multicenter, investigator-blinded, randomized, comparative trial (NCT02218372). In this trial, 148 patients were randomized, of whom 142 received either DIFICID or vancomycin in a 2:1 ratio. Randomized patients were stratified by age group as follows: 30 aged 6 months to <2 years, 49 aged 2 to <6 years, 40 aged 6 to <12 years, and 29 aged 12 to <18 years (one patient <6 months of age was enrolled in the trial). Treatment arms were balanced regarding demographics and other baseline characteristics.

Clinical response for patients <2 years of age was defined as the absence of watery stools for at least 2 consecutive days while on treatment and the patient remained well with no requirement for further CDAD therapy through 2 days after completing treatment as assessed by the Investigator. Clinical response for patients ≥2 to <18 years of age was defined as <3 unformed bowel movements for at least 2 consecutive days while on treatment and the patient remained well with no requirement for further CDAD therapy through 2 days after completing treatment as assessed by the Investigator. Sustained clinical response was defined as the proportion of treated patients with confirmed clinical response and no CDAD recurrence through 30 days after end of treatment. The clinical response and sustained clinical response overall and by age groups are presented in Table 8.
Hemodialysis continues to be the primary approach for renal replacement therapy. Vascular access (VA), particularly arteriovenous fistula or arteriovenous graft, is the preferred technique for establishing hemodialysis access due to its lower risk of infection and central venous stenosis compared to catheters. The aim of this cross-sectional investigation was to examine hemodialysis nurses' knowledge, confidence, and practices in managing VA in Saudi Arabia. This is an online cross-sectional survey study that was conducted in Saudi Arabia between June and August 2023. This study utilized a previously validated questionnaire. Examined dialysis nurses' knowledge, attitude, practice, and self-efficacy pertaining to VA cannulation and evaluation. Binary logistic regression analysis was used to identify predictors of better knowledge of dialysis VA. A total of 197 participants were involved in this study. Around one-third of the study participants (37.0%) reported that they have received specialized training in managing VA. Participants agreement (answered agree or strongly agree) on statements that examined attitudes toward dialysis VA cannulation and management was high and ranged between 75.0% and 93.0%. The majority of participants (97.5%) reported that they perform this assessment. Most nurses (65%) preferred the rope-ladder technique. Participants agreement on statements that examined self-efficacy on dialysis VA cannulation and management was high and ranged between 72.1% and 98.0%. The most commonly agreed upon statement was that "they have confident in performing hemodialysis access (arteriovenous fistula and arteriovenous graft) assessment before cannulation." With 98.0% (answered agree and strongly agree). The mean knowledge score for our study sample was 6.4 (SD: 2.0) out of 12 (53.3%); which reflects marginal-level of knowledge on dialysis VA. Binary logistic regression analysis identified that nurses who have undergraduate degree are 92% more likely to be knowledgeable on dialysis VA compared to others (P < .05). Concerning VA, the level of knowledge among hemodialysis nurses working in Saudi Arabia was inadequate. Nurses who hold an undergraduate degree are presumed to have a more extensive understanding of dialysis VA. Further education programs are necessary for HD nurses to enhance their knowledge of VA, thereby optimizing their professional practices and enhancing the outcomes for their patients.
Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
Penicillanic acid derivs. of formula (I) and their pharmaceutically permissible salts are prepd. by reacting compds. of formula (II) or their salts with a reactant (selected from alkali metal permanganate, alkaline metal permanganate, or organic peroxycarboxylic acid) to yield compds. of formula (III) or their salts, and then catalytically dehalogenating the prods. in an inert solvent. In the formulas, R1 is H or an ester residue that is easily hydrolyzed in vivo; X and Y are each H, Cl, Br, or I, but if the same they must both be Br. (I) are useful as antibiotics and beta-lactamase inhibitors
PURPOSE:A skin anatriptic agent, e.g. skin humectant, sunlight erythema inhibitor, etc., obtained by effectively utilizing blood clot or blood powder released from the livestock industry, etc., as a by-product in a large amount and incorporating globin protein prepared therefrom in the agent and producible at a low cost. CONSTITUTION:Blood serum protein part of a supernatant liquid and blood clot are separated from blood of an animal, e.g. domestic animal or domestic fowl, etc., and the blood clot part, i.e. hemoglobin consisting essentially of erythrocytes as a starting material is decomposed into blood pigment part consisting of heme and protein part consisting essentially of globin. The protein part of the globin is utilized to give a skin anatriptic agent. The resultant skin anatriptic agent is safe for the skin without viscosity though it is constituted of a relatively high-polymeric water-soluble protein.
Several lines of evidence suggest that both NMDA and oxidative stress hypotheses have been implicated in schizophrenia. Previous studies found that some NMDA-enhancing agents were able to augment efficacy of antipsychotics in the treatment of schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether a drug with antioxidant property can strengthen the efficacy of an NMDA-enhancer (NMDAE) in the treatment of schizophrenia remains unknown. Therefore, this study aims to compare NMDAE plus a drug with antioxidant property and NMDAE plus placebo in the treatment of schizophrenia. The subjects are the schizophrenia patients who remain symptomatic while having been stabilized with antipsychotic treatment. They keep their original treatment and are randomly, double-blindly assigned into two treatment groups for 12 weeks: (1) NMDAE plus Antioxidant agent (AO), or (2) NMDAE plus placebo. Clinical performances and side effects are measured at weeks 0, 2, 4, 6, 9, and 12. Cognitive functions are assessed at baseline and at endpoint of treatment by a battery of tests. The efficacies of NMDAE plus AO and NMDAE plus placebo will be compared.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.
UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
Oropharyngeal dysphagia (OD) is a common finding in patients with neurogenic disorders.

Swallowing disorder can be acute or chronic in nature. For example, acute OD is observed in patients after stroke, head trauma, neurosurgical intervention, or in patients with Guillain-Barré syndrome. Chronic OD may develop in patients who do not recover after a stroke. Degenerative OD, Parkinson's disease, amyotrophic lateral sclerosis, myasthenia gravis, Huntington's disease, myotonic dystrophy type 1 and multiple sclerosis It is seen in patients with progressive neurological diseases. The prevalence of OD in neurogenic patients varies from 3% to 50% in stroke patients and up to almost 100% in patients with Huntington's disease. The OD can lead to weight loss, malnutrition, social isolation, aspiration pneumonia, and reduced health-related quality of life (QoL). Some studies have reported that dysphagia-specific QoL is weakly associated with OD severity measured using, among other things, fiberoptic endoscopic evaluation of swallowing (FEES) and videofluoroscopy of swallowing (VFS). Therefore, dysphagia-specific QoL questionnaires used alongside these instrumental assessments add value by providing insight into patients' perception of OD, which can be taken into account in the treatment plan. There are dysphagia-specific quality-of-life questionnaires that are actively used today: Swallowing Quality of Life Questionnaire (SWAL-QOL, 44 items), Swallowing Disability Index (30 items), Dysphagia Handicap Index (25 items) and M.D. Anderson Dysphagia Inventory (MDADI, 20 items). Multidisciplinary dysphagia clinics in our country mostly focus on the head and neck. It is visited by patients with OD of oncological or neurological origin.The M. D. Anderson dysphagia inventory is an easier inventory to perform since it has a smaller number of questions and contains more standard questions compared to other currently used questionnaires. Other questionnaires, such as the SWAL-QOL-TR and the Swallowing Disability Index, are longer than the MDADI and take more time to complete. The purpose of this study is M.D. Validity of the Turkish version of the Anderson Dysphagia Inventory for the Turkish population, reliability and cultural adaptation.
Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
The second group will consist of (150) RA subjects that did not respond to "DMARDs". These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists.
Mechanosensitive ion channels sense force and pressure in immune cells to drive the inflammatory response in highly mechanical organs. Here, we report that Piezo1 channels repress group 2 innate lymphoid cell (ILC2)-driven type 2 inflammation in the lungs. Piezo1 is induced on lung ILC2s upon activation, as genetic ablation of Piezo1 in ILC2s increases their function and exacerbates the development of airway hyperreactivity (AHR). Conversely, Piezo1 agonist Yoda1 reduces ILC2-driven lung inflammation. Mechanistically, Yoda1 inhibits ILC2 cytokine secretion and proliferation in a KLF2-dependent manner, as we found that Piezo1 engagement reduces ILC2 oxidative metabolism. Consequently, in vivo Yoda1 treatment reduces the development of AHR in experimental models of ILC2-driven allergic asthma. Human-circulating ILC2s express and induce Piezo1 upon activation, as Yoda1 treatment of humanized mice reduces human ILC2-driven AHR. Our studies define Piezo1 as a critical regulator of ILC2s, and we propose the potential of Piezo1 activation as a novel therapeutic approach for the treatment of ILC2-driven allergic asthma.